Ipilimumab-nivolumab and axitinib-pembrolizumab combinations produce similar survival times
When ipilimumab plus nivolumab or axitinib plus pembrolizumab are used [...]
Nivolumab compared to cabozantinib as a second- or third-line treatment
This study looked at real world data from people with [...]
Outcomes of patients who stopped immunotherapy due to immune-related side effects
Immunotherapy has changed the way advanced renal cell carcinoma (RCC) [...]
Atezolizumab plus bevacizumab does not improve survival in kidney cancer
Results from the IMmotion151 phase III clinical trial were published [...]
Cabozantinib in combination with atezolizumab for advanced kidney cancer
This phase Ib study reports the results of a combination [...]
Outcomes and side effects after first-line treatment with combination therapies for kidney cancer
This report looked at the results from 4 studies comparing [...]
Role of nephrectomy for metastatic kidney cancer in the immunotherapy era
Three phase III clinical trials (Keynote 426, Checkmate 9ER and [...]
EIKCS 2021: Combination therapies for metastatic kidney cancer: Which Approach?
The use of combination therapies for the first-line treatment of [...]
Updated results from a trial with belzutifan for people with advanced kidney cancer
Kidney cancers frequently have mutations in the von Hippel-Lindau (VHL) gene, [...]
Atezolizumab plus bevacizumab for metastatic kidney cancer patients with disease progression on atezolizumab or sunitinib
A study published in European Urology this month looks at [...]
